Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02139072 · ClinicalTrials.gov registry record
CoaguChek XS in Antiphospholipid Antibody Syndrome (APL) Patients
A clinical trial of Antiphospholipid Antibody Syndrome, sponsored by University of Florida.
- Completed
- Registry status
- 60
- Enrollment target
- 1
- Study location
NCT02139072 is a study of Antiphospholipid Antibody Syndrome that has completed, run by University of Florida. The registered enrollment target is 60 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02139072, a study of Antiphospholipid Antibody Syndrome, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see if the CoaguChek XS is accurate in measuring International Normalized Ratio (INR) in patients with Antiphospholipid Antibody Syndrome (APL) receiving warfarin therapy.
Conditions Studied
Interventions
- DEVICE CoaguChek XS
- PROCEDURE Standard Lab Draw
Study Locations (1)
Florida
- UF and Shands Health - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2015-03 |
| Est. Completion | 2016-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02139072
The ClinicalTrials.gov registry entry for NCT02139072 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Antiphospholipid Antibody Syndrome appearing as the primary indexed condition, and to 2 interventions - of which CoaguChek XS is the first listed.
NCT02139072 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT02139072 about?
NCT02139072 is a clinical study titled "CoaguChek XS in Antiphospholipid Antibody Syndrome (APL) Patients". The purpose of this study is to see if the CoaguChek XS is accurate in measuring International Normalized Ratio (INR) in patients with Antiphospholipid Antibody Syndrome (APL) receiving warfarin therapy.
What is the current status of trial NCT02139072?
This trial is currently completed. The enrollment target is 60 participants. The study started on 2015-03. Estimated completion is 2016-01.
What conditions does trial NCT02139072 study?
This clinical trial studies the following conditions: Antiphospholipid Antibody Syndrome.
What interventions are being tested in trial NCT02139072?
The interventions under investigation include: CoaguChek XS (DEVICE), Standard Lab Draw (PROCEDURE).
Who is sponsoring clinical trial NCT02139072?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02139072 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Antiphospholipid Antibody Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.